This study provides pivotal prospective evidence for treatment selection in patients with HER2-positive mCRC, highlighting the potential of HER2 gene copy number as a predictive biomarker and offering direct guidance for precision therapy strategies in colorectal cancer.
Literature Overview
This article, 'Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients with RAS/BRAF wild-type, HER2-positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase 2 Trial,' published in the Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, systematically investigates the efficacy and safety of dual HER2-targeted inhibition (TP regimen) versus standard anti-EGFR chemotherapy combination (CETIRI regimen) in patients with RAS/BRAF wild-type, HER2-positive metastatic colorectal cancer (mCRC). Using a multicenter randomized design, the study aims to establish optimal second- or third-line treatment strategies for this specific molecular subtype. Further analyses reveal the critical role of HER2 gene copy number (GCN) in guiding treatment selection, providing important evidence for precision medicine.Background Knowledge
Metastatic colorectal cancer (mCRC) is a heterogeneous disease, with approximately 2–3% of cases exhibiting amplification or protein overexpression of the ERBB2 (i.e., HER2) gene, increasing to 5–7% in RAS/BRAF wild-type tumors. These HER2-positive mCRC patients typically respond poorly to anti-EGFR therapies (such as cetuximab), with a median progression-free survival (PFS) of only 2–3 months, suggesting that the EGFR pathway may be bypassed via HER2 signaling in this subtype. Therefore, HER2-targeted therapies represent a key strategy to overcome resistance. Previous single-arm studies have demonstrated that dual HER2 blockade (e.g., trastuzumab combined with pertuzumab or tucatinib) achieves objective response rates of 30–40% in heavily pretreated HER2-positive mCRC, showing significant antitumor activity. However, the lack of head-to-head comparative data has hindered clinical decision-making. Moreover, it remains unclear whether the extent of HER2 amplification affects treatment response, necessitating prospective validation. This study addresses these gaps through the S1613 trial, directly comparing TP and CETIRI regimens to clarify the role of HER2-targeted therapy in mCRC and explore potential predictive factors such as HER2 copy number, thereby providing evidence for individualized treatment.
Research Methods and Experiments
The study employed a multicenter, open-label, randomized phase 2 design, enrolling 54 patients with centrally confirmed HER2-positive (IHC 3+ or IHC 2+/ISH amplified) RAS/BRAF wild-type mCRC, who were randomly assigned to receive either the TP regimen (trastuzumab + pertuzumab) or the CETIRI regimen (cetuximab + irinotecan). All patients received standardized therapy until disease progression or intolerable toxicity. The design allowed patients in the CETIRI group to cross over to the TP regimen upon progression, enabling assessment of sequential treatment effects. The primary endpoint was progression-free survival (PFS); secondary endpoints included objective response rate (ORR), overall survival (OS), and safety. Key exploratory analyses evaluated the predictive value of centrally assessed HER2 gene copy number (GCN) and HER2/CEP17 ratio (HCR) on treatment efficacy. Survival analyses were performed using Kaplan-Meier methods and Cox regression models, while ORR comparisons used the Cochran-Mantel-Haenszel test.Key Conclusions and Perspectives
Research Significance and Prospects
This study is the first to validate, within a randomized controlled framework, the predictive value of HER2 amplification levels for treatment response, establishing HER2 GCN as a critical biomarker for guiding treatment decisions in mCRC. This will drive more refined molecular stratification of HER2-positive mCRC in clinical practice, enabling truly precise therapy. Future studies should further explore the relationship between continuous HER2 copy number and treatment efficacy, rather than relying on binary cutoffs, to optimize threshold values. Additionally, the findings support early assessment of HER2 status and copy number after progression on first-line therapy to inform second-line treatment decisions.
From a drug development perspective, this study provides a reference for designing clinical trials of novel HER2-targeted agents (e.g., ADCs like trastuzumab deruxtecan), suggesting that HER2 copy number should be used as an inclusion or stratification criterion. Moreover, the results challenge the traditional notion that 'HER2-positive implies anti-EGFR resistance' by showing that patients with low HER2 amplification may still benefit from anti-EGFR therapy, necessitating further investigation into the underlying mechanisms. This provides a theoretical foundation for developing combination strategies (e.g., dual HER2 and EGFR inhibition).
In terms of disease modeling, the study underscores the importance of developing PDX or organoid models that reflect varying levels of HER2 copy number to simulate clinical heterogeneity in vitro. Such models can be used to further investigate the dynamic regulation of HER2 signaling pathways and resistance evolution, accelerating drug screening and combination strategy development. In particular, integrating single-cell sequencing and spatial transcriptomics holds promise for deciphering the role of the tumor microenvironment in modulating response to HER2-targeted therapies.
Conclusion
This study sets a new benchmark for precision therapy in HER2-positive metastatic colorectal cancer. It not only confirms the feasibility and favorable tolerability of the trastuzumab plus pertuzumab (TP) regimen as a chemotherapy-free option, but more importantly, establishes for the first time through prospective data the critical predictive value of HER2 gene copy number (GCN) in treatment decision-making. For patients with high amplification (GCN≥20), the TP regimen is significantly superior to the traditional cetuximab plus irinotecan (CETIRI) regimen and should be the preferred choice; conversely, patients with low GCN may still benefit from anti-EGFR therapy. This finding fundamentally changes the clinical management strategy for HER2-positive mCRC, emphasizing the necessity of quantitative rather than qualitative assessment of HER2 status. From bench to bedside, this study advances a paradigm shift from 'one-size-fits-all' to 'stratified treatment,' offering patients more individualized therapeutic pathways. In the future, integrating HER2 copy number with other co-mutations (e.g., PIK3CA, TP53) and dynamic ctDNA monitoring may enable the construction of even more precise predictive models, further optimizing treatment sequences and combination strategies, ultimately improving long-term survival outcomes for this rare but targetable subtype.
